These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 15590403)
1. Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin. D'Ambrosio RL; D'Andrea G; Cappucci F; Chetta M; Di Perna P; Brancaccio V; Grandone E; Margaglione M Haematologica; 2004 Dec; 89(12):1510-6. PubMed ID: 15590403 [TBL] [Abstract][Full Text] [Related]
2. Interindividual variability in sensitivity to warfarin--Nature or nurture? Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010 [TBL] [Abstract][Full Text] [Related]
3. Genetic modulation of oral anticoagulation with warfarin. Margaglione M; Colaizzo D; D'Andrea G; Brancaccio V; Ciampa A; Grandone E; Di Minno G Thromb Haemost; 2000 Nov; 84(5):775-8. PubMed ID: 11127854 [TBL] [Abstract][Full Text] [Related]
4. Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort. Moridani M; Fu L; Selby R; Yun F; Sukovic T; Wong B; Cole DE Clin Biochem; 2006 Jun; 39(6):606-12. PubMed ID: 16630605 [TBL] [Abstract][Full Text] [Related]
5. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971 [TBL] [Abstract][Full Text] [Related]
6. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Kamali F; Khan TI; King BP; Frearson R; Kesteven P; Wood P; Daly AK; Wynne H Clin Pharmacol Ther; 2004 Mar; 75(3):204-12. PubMed ID: 15001972 [TBL] [Abstract][Full Text] [Related]
7. Warfarin or acenocoumarol: which is better in the management of oral anticoagulants? Barcellona D; Vannini ML; Fenu L; Balestrieri C; Marongiu F Thromb Haemost; 1998 Dec; 80(6):899-902. PubMed ID: 9869157 [TBL] [Abstract][Full Text] [Related]
8. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Herman D; Locatelli I; Grabnar I; Peternel P; Stegnar M; Mrhar A; Breskvar K; Dolzan V Pharmacogenomics J; 2005; 5(3):193-202. PubMed ID: 15824753 [TBL] [Abstract][Full Text] [Related]
9. Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers. Mlynarsky L; Bejarano-Achache I; Muszkat M; Caraco Y Eur J Clin Pharmacol; 2012 May; 68(5):617-27. PubMed ID: 22071881 [TBL] [Abstract][Full Text] [Related]
10. Warfarin sensitivity and genetic polymorphisms: should pharmacokinetic screening be part of anticoagulant dosing decisions? Baglin TP Clin Adv Hematol Oncol; 2003 Nov; 1(11):656-7. PubMed ID: 16258463 [No Abstract] [Full Text] [Related]
11. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Caraco Y; Blotnick S; Muszkat M Clin Pharmacol Ther; 2008 Mar; 83(3):460-70. PubMed ID: 17851566 [TBL] [Abstract][Full Text] [Related]
12. Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer. Ruud E; Holmstrøm H; Bergan S; Wesenberg F Pediatr Blood Cancer; 2008 Mar; 50(3):710-3. PubMed ID: 17226852 [TBL] [Abstract][Full Text] [Related]
14. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. D'Andrea G; D'Ambrosio RL; Di Perna P; Chetta M; Santacroce R; Brancaccio V; Grandone E; Margaglione M Blood; 2005 Jan; 105(2):645-9. PubMed ID: 15358623 [TBL] [Abstract][Full Text] [Related]
15. Warfarin resistance with poor CYP2C9 activity and CYP2C9*1*2 genotype. Dericioglu N; Babaoglu MO; Saygi S; Bozkurt A; Yasar U Ann Pharmacother; 2004 May; 38(5):899. PubMed ID: 15039471 [No Abstract] [Full Text] [Related]
16. A novel sequence variant in exon 7 of CYP2C9 gene (CYP2C9*24) in a patient on warfarin therapy. Herman D; Peternel P; Stegnar M; Breskvar K; Dolzan V Thromb Haemost; 2006 Jan; 95(1):192-4. PubMed ID: 16543980 [No Abstract] [Full Text] [Related]
17. CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences. Takahashi H; Wilkinson GR; Padrini R; Echizen H Clin Pharmacol Ther; 2004 May; 75(5):376-80. PubMed ID: 15116049 [No Abstract] [Full Text] [Related]
18. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants. Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH Clin Pharmacol Ther; 2005 Jun; 77(6):479-85. PubMed ID: 15961979 [TBL] [Abstract][Full Text] [Related]
19. [The influence of CYP2C9 genetic polymorphism on the pharmacokinetics and pharmacodynamics of warfarin in patients with constant atrial fibrillation]. Sychev DA; Mikheeva IuA; Kropacheva ES; Ignat'ev IV; Bulytova IuM; Ramenskaia GV; Dobrovol'skiĭ AB; Panchenko EP; Kukes VG Klin Med (Mosk); 2007; 85(1):57-60. PubMed ID: 17419358 [TBL] [Abstract][Full Text] [Related]
20. The influence of (R)- and (S)-warfarin, vitamin K and vitamin K epoxide upon warfarin anticoagulation. Kamali F; Edwards C; Butler TJ; Wynne HA Thromb Haemost; 2000 Jul; 84(1):39-42. PubMed ID: 10928467 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]